Both metal complexes and organic molecules are widely used for the treatment of various
diseases including cancer–in addition to surgery and radiotherapy. Recent years have …

Ruthenium‐based anticancer chemotherapies are making significant advances in clinical
trials. Until recently, the focus has been on coordination complexes, and mechanisms such …

Ruthenium anticancer drugs have attracted an increasing interest in the last 20 years and
two of them have entered clinical trials. Compared to platinum drugs, the complexes based …

Based on the clinical success of platinum-based anti-cancer drugs such as cisplatin,
carboplatin and oxaliplatin, a variety of other metal-based anti-cancer compounds are being …

Organometallic ruthenium compounds that are effective anticancer and antimetastasis
agents are currently under intensive investigation (see also the article by Peter Sadler in this …

Abstract Ruthenium (II)-arene RAPTA-type compounds have been extensively explored for
their medicinal properties. Herein a comprehensive review of this class of compounds is …

Anticancer metallodrugs based on ruthenium and osmium are among the most investigated
and advanced non-platinum metallodrugs. Inorganic drug discovery with these agents has …

Organometallic compounds offer broad scope for the design of therapeutic agents, but this
avenue has yet to be widely explored. A key concept in the design of anticancer complexes …

GLOBOCAN 2012 estimates 14.1 million new cancer cases and 8.2 million cancer-related
deaths worldwide. Cancer is rapidly becoming a major public health concern in India as …

Interest in Ru anticancer drugs has been growing rapidly since NAMI-A ((ImH+)[RuIIICl4
(Im)(S-dmso)], where Im= imidazole and S-dmso= S-bound dimethylsulfoxide) or KP1019 …